



**Company Contact:**  
**Richard Gabriel**  
**CEO and President**  
**941 366-3400**

**-or-**

**Ron Stabiner**  
**The Wall Street Group, Inc.**  
**212-888-4848**

**FOR IMMEDIATE RELEASE:**

**DNAPRINT GENOMICS PRESIDENT & CEO RICHARD GABRIEL  
INTERVIEWED BY WALL STREET REPORTER**

**SARASOTA, Fla., Aug. 18, 2006 – DNAPrint Genomics, Inc. (OTCBB: DNAG)** today announced that President and Chief Executive Officer Richard Gabriel conducted an interview with The Wall Street Reporter on Tuesday, August 15, 2006.

During the interview, Mr. Gabriel provided an overview of the Company's operations, listing the various activities in each division and outlining their distinctive plans for growth.

"The strategy has been to focus on increasing revenue, and we are doing that, as our quarterly results show," Mr. Gabriel stated in the interview. "Revenue is up for the half year by a pretty good amount, and we hope to continue that trend through the end of the year."

Mr. Gabriel also gave insights into the revenue potential for DNA research and an update on the development of compounds to treat various diseases. He elaborated on the revenue potential for the Company's relationships with Biofrontera of Germany, in which the company has a significant ownership stake, as well as the continuing relationship with Harvard University's Beth Israel Deaconess Hospital and the new relationship with Emory University's Center for Medical Genomics.

The interview is available for streaming by going to <http://www.wallstreetreporter.com/profile.php?id=19412>. Free registration is required to enter the site. The interview will be available in the site's archive until November 15, 2006.

**About DNAPrint Genomics, Inc.**

DNAPrint Genomics, Inc. ([www.dnaprint.com](http://www.dnaprint.com)) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to [www.dnaprint.com](http://www.dnaprint.com) for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools

(MORE)

when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

**Forward-Looking Statements**

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

##